News | May 29, 2022
JBCL rebrands as JB
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
'Hello Skin' has been developed in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists)
Investment with representation on the Board of Directors and technical know-how
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
Key senior hire will partner with Allison Ceraso, President and CCO, bolstering agency leadership amongst continued network momentum
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
This new fund is amongst the largest for the sector in India
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
